Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05598060
Other study ID # 2022-0743
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 1, 2022
Est. completion date February 1, 2024

Study information

Verified date September 2022
Source Second Affiliated Hospital, School of Medicine, Zhejiang University
Contact Qichun Wei, MD/PhD
Phone 187783521
Email qichun_wei@zju.deu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hepatocellular carcinoma (HCC) is the sixth prevalent malignancy worldwide. Although surgical excision is considered the standard treatment for resectable HCC, a high rate of postoperative recurrence was observed after partial hepatectomy, with a marginal recurrence rate up to 30%. Narrow margin resection may be the most appropriate procedure for centrally located HCC because the premise for survival is the conservation of more normal liver parenchyma. Unfortunately, narrow margin resection has been reported to contribute to poor survival outcomes. However, no (neo)adjuvant therapy before (or after) hepatectomy is generally considered to be effective in reducing post-operative recurrence. Radiotherapy (RT) has been well used in many solid malignant tumors as an (neo)adjuvant to surgical treatment, including HCC. SBRT has shown encouraging rates of local control for HCC. Compared with standard fractionation radiation, SBRT can achieve more precise delivery of high-dose radiation beams to the lesion, obtaining a much smaller target volume. Meanwhile, it could be finished in a short period which can bring more convenience to patients. Recently, several study and randomized controlled trials revealed the survival benefit of adjuvant RT (IMRT and SBRT) in patients with HCC. However, there are still lack of exploration for the efficacy of neoadjuvant SBRT. This study is to analyze the safety of preoperative SBRT followed by hepatectomy for centrally located hepatocellular carcinoma.


Recruitment information / eligibility

Status Recruiting
Enrollment 15
Est. completion date February 1, 2024
Est. primary completion date November 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Aged =18 years; 2. Confirmed diagnosis of HCC. The diagnosis can be established radiographically by the criteria of the American Association for the Study of the Liver (AASLD), or by histologic diagnosis from the core biopsy; 3. Centrally located hepatocellular carcinoma and medically fit to undergo surgery as determined by the Multiple Disciplinary Team (MDT); 4. BCLC stage A 5. No imaging evidence of direct invasion of stomach, duodenum, small intestine, large intestine or diaphragm of the intrahepatic lesions to be treated with radiotherapy; 6. Child-Pugh class A and B7; 7. ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1; 8. Willing to provide tissue from an excisional biopsy of a tumor lesion; 9. For patients with active HBV: HBV DNA < 2000 IU/mL during screening, and have initiated anti-HBV treatment at least 7 days prior to SBRT and willingness to continue anti-HBV treatment during the study; 10. Adequate organ and marrow function as defined below: 1)Marrow: absolute neutrophil count =1.5×109/L; platelets =50×109/L; hemoglobin =90g/L; 2)Liver: total bilirubin =3× institutional upper limit of normal (ULN); AST(aspartate aminotransferase) or ALT(alanine aminotransferase) = 5× institutional ULN; albumin =29g/L; 3)Kidney: creatinine = 1.5× institutional ULN or estimated glomerular filtration rate (GFR) =50 mL/min/1.73 m2 (according to the Cockcroft-Gault formula); 11. Women of childbearing potential must be willing to use a highly effective method of contraception for the course of the study through 30 days after radiotherapy. Female patient of childbearing potential should have a negative serum pregnancy test before 72h of her first treatment. Sexually active males must agree to use an adequate method of contraception starting with the treatment through 4 months after radiotherapy. Exclusion Criteria: 1. Have received local or systemic treatments in the past, including but not limited to TACE, immunotherapy, targeted therapy, radiotherapy, radiofrequency therapy, etc.; 2. Severe bleeding tendency or coagulation dysfunction within the previous 6 months; 3. Extrahepatic metastasis; 4. Prior abdominal irradiation; 5. Any major surgery within 1 months prior to enrolment; 6. Known history of active Bacillus Tuberculosis (TB) 7. Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer. 8. Active infection requiring systemic therapy; 9. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy; 10. Known psychiatric or substance abuse disorders ; 11. Pregnant or breastfeeding; 12. Known history of human immunodeficiency virus (HIV: HIV 1/2 antibodies); 13. Received a live vaccine within 30 days before radiotherapy.

Study Design


Intervention

Radiation:
Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.
Neoadjuvant stereotactic body radiation therapy (Multiple ascending dose) followed by hepatectomy for centrally located hepatocellular carcinoma.

Locations

Country Name City State
China The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang

Sponsors (1)

Lead Sponsor Collaborator
Second Affiliated Hospital, School of Medicine, Zhejiang University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety and tolerability of radiotherapy followed by hepatectomy : Incidence of Treatment-Emergent Adverse events (CTCAE v5.0) Safety and tolerability of radiotherapy followed by hepatectomy 3 months after resection
Secondary Local recurrence free survival Local recurrence free survival from date of enrollment to date of first documented local recurrence. Assessed up to 12 months
Secondary Progression free survival Progression free survival from date of enrollment to the date of first documented progression. Assessed up to 12 months
Secondary Overall survival Overall survival from date of enrollment to the date of death from any cause. Assessed up to 12 months
Secondary Time to Progress Time to Progress from date of enrollment to the date of progress. Assessed up to 12 months
Secondary Quality of life by EORTC QLQ-C30 Quality of life by EORTC QLQ-C30 through study completion, an average of 1 year
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03651154 - Hypovolemic Phlebotomy to Reduce Blood Transfusions in Major Hepatic Resections N/A
Completed NCT02041871 - Interest of PReOPerative Immunonutrition in Liver Surgery for Cancer N/A
Recruiting NCT06044909 - Multimodal Image Registration for Helping Laparoscopic Liver Surgery Guidance
Recruiting NCT05523713 - Development and Validation of a Predictive Score for Surgical Site Infections Phase 3
Recruiting NCT03715517 - Spinal Anesthesia For Enhanced Recovery After Liver Surgery N/A
Recruiting NCT06130436 - Application of Perioperative Remote Ischemic Conditioning in Patients Undergoing Hepatectomy N/A
Recruiting NCT04218253 - Clinical Application of Nutrition Support Package Before Hepatectomy N/A
Recruiting NCT04559269 - Microsleep 1, Micro-sleep During Maintenance Wakefulness Tests
Completed NCT03611426 - Topical rhThrombin as an Adjunct to Hemostasis During Segmental Hepatectomy Phase 1/Phase 2
Completed NCT02817321 - Thoracic Paravertebral Block : Effect on Acute Pain and Chronic Pain of Hepatectomy With Right J-shape Subcostal Incision N/A
Completed NCT03793933 - ACS-NSQIP Calculator for Liver Surgery
Recruiting NCT03540537 - A Trial Comparing Quadratus Lumborum Block (QLB) and Paravertebral Block (PVTB) for Postoperative Analgesia in Hepatectomy N/A
Recruiting NCT06166186 - Effect of Intraoperative Music on Inflammatory Response in Donor Hepatectomy N/A
Not yet recruiting NCT02758977 - Associating Liver Partition With Portal Vein Ligation for Staged Hepatectomy (ALPPS) vs. Two-Stage Hepatectomy (TSH) for Marginally Resectable Colorectal Liver Metastases (CRLM) N/A
Completed NCT01469442 - Postoperative Biliary Fistula Prevention After Hepatectomy N/A
Completed NCT00730743 - Study on Clinical Outcome of Vascular Inflow Occlusion in Open Liver Resection N/A
Recruiting NCT02198625 - Influence of Moderate Inspired Oxygen Fraction (FiO2) and Protective Ventilation on Postoperative Pulmonary Complication Phase 4
Completed NCT01194843 - Placebo-controlled Evaluation of Ropivacaine Efficacy by Local Infiltrations N/A
Completed NCT00200148 - Acute Normovolemic Hemodilution Versus Standard Intraoperative Management in Patients Having Hepatic Resection and Pancreaticoduodenectomy Phase 3
Recruiting NCT03323359 - Efficacy and Tolerability of Hemopatch After Hepatic Resection N/A